Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus

被引：8

作者：

Canas, E

Pachon, J

GarciaPesquera, F

Castillo, JR

Viciana, P

Cisneros, JM

JimenezMejias, ME

机构：

[1] HOSP UNIV VIRGEN ROCIO,INFECT DIS UNIT,E-41013 SEVILLE,SPAIN

[2] HOSP UNIV VIRGEN ROCIO,DEPT NUCL MED,E-41013 SEVILLE,SPAIN

[3] HOSP UNIV VIRGEN ROCIO,CLIN PHARMACOL UNIT,E-41013 SEVILLE,SPAIN

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1996年 / 40卷 / 01期

关键词：

D O I：

10.1128/AAC.40.1.230

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Pharmacokinetic parameters of zidovudine (ZDV) were not altered in 16 patients receiving concomitant therapy with ZDV and trimethoprim-sulfamethoxazole by oral administration. ZDV areas under the concentration-time curves were (means +/- standard deviations) 1.80 +/- 0.70 and 1.69 +/- 0.64 mu g . h/ml in the absence and presence of trimethoprim-sulfamethoxazole, respectively. ZDV clearances were 1.57 +/- 0.61 and 1.74 +/- 0.66 liters/h/kg, respectively.

引用

页码：230 / 233

页数：4

共 50 条

[1] Desensitization to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus
Ruskin, J
Gluckstein, D
CLINICAL INFECTIOUS DISEASES, 1996, 22 (02) : 396 - 397
[2] Restarting trimethoprim-sulfamethoxazole after a hypersensitivity reaction in patients infected with the human immunodeficiency virus
EversonMays, RE
Weidle, PJ
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (13) : 1545 - 1550
[3] A SEVERE, UNUSUAL REACTION TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
KELLY, JW
DOOLEY, DP
LATTUADA, CP
SMITH, CE
CLINICAL INFECTIOUS DISEASES, 1992, 14 (05) : 1034 - 1039
[4] EFFICACY AND SAFETY OF DESENSITIZATION TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS
PIKETTY, C
GILQUIN, J
KAZATCHKINE, MD
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (02): : 611 - 611
[5] MANAGEMENT OF ADVERSE REACTIONS TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS
JUNG, AC
PAAUW, DS
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (21) : 2402 - 2406
[6] Rhabdomyolysis in human immunodeficiency virus - Positive patients taking trimethoprim-sulfamethoxazole
Singer, SJ
Racoosin, JA
Viraraghavan, R
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 233 - 234
[7] A SEVERE SYSTEMIC REACTION TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN A PATIENT INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS
MARTIN, GJ
PAPARELLO, SF
DECKER, CF
CLINICAL INFECTIOUS DISEASES, 1993, 16 (01) : 175 - 176
[8] A SEVERE HYPERSENSITIVE REACTION TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN A PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
MARINAC, JS
STANFORD, JF
CLINICAL INFECTIOUS DISEASES, 1993, 16 (01) : 178 - 179
[9] Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients: Impact on risk for infectious diseases
Dworkin, MS
Williamson, J
Jones, JL
Kaplan, JE
CLINICAL INFECTIOUS DISEASES, 2001, 33 (03) : 393 - 398
[10] EFFECT OF RIFABUTIN ON THE PHARMACOKINETICS OF ZIDOVUDINE IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
GALLICANO, K
SAHAI, J
SWICK, L
SEGUIN, I
PAKUTS, A
CAMERON, DW
CLINICAL INFECTIOUS DISEASES, 1995, 21 (04) : 1008 - 1011

← 1 2 3 4 5 →